1130
1. Introduction In early 2008, the European Commission launched a wide-ranging inquiry into alleged anti-competitive conduct in the pharmaceutical sector. The Sector Inquiry closely investigated, amongst others, certain practices by originator drug companies aimed at delaying the entry into (...)